Scott Friedman, MD
Ophthalmology · Lakeland, FLNPI 1497842314
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (43.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Genentech USA, Inc. at 28.4% of the total. Reporting peaked in 2023 at $11,090 and has fallen 56.7% since, to $4,802 in 2025. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 208 payments — averaging $121.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$7K
- Amgen$5K
- Ocular Therapeutix, Inc.$3K
- Apellis Pharmaceuticals, Inc.$3K
- Regeneron Healthcare Solutions, Inc.$2K
- Regeneron$933
- plus $4K from 25 others
Across 469 payments — averaging $3589.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$716K
- Bayer$266K
- Boehringer Ingelheim International GmbH$208K
- Amgen$162K
- Ocular Therapeutix, Inc.$149K
- Roche TCRC, Inc.$85K
- plus $97K from 4 others
What the payments were for
- Consulting fees$10,81243%
- Travel & lodging$3,32013%
- Food & beverage$11,05944%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 59 | $7,154 |
| Amgen(2 entities) | 11 | $4,708 |
| Ocular Therapeutix, Inc. | 5 | $3,185 |
| Apellis Pharmaceuticals, Inc. | 18 | $3,091 |
| Regeneron Healthcare Solutions, Inc. | 25 | $1,692 |
| Regeneron | 12 | $933 |
| AbbVie(2 entities) | 19 | $535 |
| Kowa Research Institute, Inc. | 1 | $500 |
| Harrow Eye, LLC | 7 | $417 |
| Eyepoint US, Inc. | 3 | $305 |
| Alimera Sciences, Inc. | 5 | $297 |
| Sun Pharmaceutical Industries Inc. | 3 | $270 |
| Sight Sciences, Inc. | 2 | $249 |
| Alcon | 2 | $242 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $242 |
| Astellas Pharma US Inc | 5 | $176 |
| ANI Pharmaceuticals, Inc. | 3 | $164 |
| Novartis | 3 | $153 |
| NEW World Medical,inc. | 1 | $142 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $129 |
| Dompe US, Inc. | 1 | $121 |
| Bausch & Lomb Americas Inc. | 5 | $107 |
| Ivantis, Inc | 1 | $101 |
| Coherus Oncology, Inc. | 3 | $96 |
| Boehringer Ingelheim | 1 | $46 |
| Pfizer | 2 | $35 |
| Biogen | 2 | $33 |
| Glaukos Corporation | 1 | $29 |
| Rxsight Inc | 1 | $25 |
| Rayner Intraocular Lenses Limited | 1 | $16 |
| Mimedx Group, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$6,148
- LUMAKRAS$3,932
- EYLEA$1,343
- Lucentis$911
- TEPEZZA$588
- EYLEA HD$497
- Syfovre$493
- IHEEZO$289
- CEQUA$240
- Hydrus Microstent$226
- OMNI(R) SURGICAL SYSTEM (US)$149
- SION SURGICAL INSTRUMENT$149
- Ahmed Glaucoma Valve$142
- Kahook Dual Blade$142
- YUTIQ$124
- PROLENSA$122
- Oxervate$121
- Unity$117
- DURYSTA$116
- PURIFIED CORTROPHIN GEL$115
How this compares
$25,209 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 186 | $5,535 |
| Ciprofloxacin Hcl | 106 | $1,328 |
| Timolol Maleate | 27 | $852 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 50 | $652 |
| Latanoprost | 24 | $217 |
| Diclofenac Sodium | 17 | $162 |
| Brimonidine Tartrate | 18 | $80 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Lakeland
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
- Harold BrooksTallahassee$683K
- Robert WeinstockLargo$605K
- William TrattlerMiami$579K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.